This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ashton, C. H.
Right arrow Articles by Tyrer, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ashton, C. H.
Right arrow Articles by Tyrer, S. P.

The British Journal of Psychiatry 157: 232-238 (1990)
© 1990 The Royal College of Psychiatrists

A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users

CH Ashton, MD Rawlins and SP Tyrer
Department of Pharmacological Sciences, University of Newcastle upon Tyne.

A double-blind placebo-controlled trial of 23 chronic benzodiazepine users showed that overall, buspirone did not appear to be helpful in alleviating benzodiazepine withdrawal symptoms. Buspirone (5 mg t.d.s.) or placebo was administered for four weeks before, during and after diazepam withdrawal. Patients taking buspirone had a markedly higher dropout rate (seven out of 11) than those taking placebo (one out of 12). Mean daily diazepam dosage at entry was significantly higher in the buspirone group, but overall initial diazepam dosage was not related to outcome. Higher subjectively rated anxiety at the start of withdrawal was significantly related to higher dropout rate, irrespective of treatment, and was greater (although not significantly so) in the buspirone group.


This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
R. C. O. Voshaar, J. E. Couvee, A. J. L. M. Van Balkom, P. G. H. Mulder, and F. G. Zitman
Strategies for discontinuing long-term benzodiazepine use: Meta-analysis
The British Journal of Psychiatry, September 1, 2006; 189(3): 213 - 220.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt
Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
J Psychopharmacol, September 1, 2004; 18(3): 293 - 335.
[PDF]

Home page
 J PsychopharmacolHome page
H. Ashton and A. H. Young
GABA-Ergic Drugs: Exit Stage Left, Enter Stage Right
J Psychopharmacol, June 1, 2003; 17(2): 174 - 178.
[Abstract] [PDF]

Home page
 J PsychopharmacolHome page
S. Morton and M. Lader
Buspirone treatment as an aid to benzodiazepine withdrawal
J Psychopharmacol, January 1, 1995; 9(4): 331 - 335.
[Abstract] [PDF]